Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis | Zendy

Rebecca S. Pettit | Zendy; Natalie Neu | Zendy; Jeffrey J. Cies | Zendy; Craig Lapin | Zendy; Marianne S. Muhlebach | Zendy; Kimberly J. Novak | Zendy; Sean Nguyen | Zendy; Lisa Saiman | Zendy; David P. Nicolau | Zendy; Joseph L. Kuti | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Population pharmacokinetics of meropenem administered as a prolonged infusion in children with cystic fibrosis

Author(s) -

Rebecca S. Pettit,

Natalie Neu,

Jeffrey J. Cies,

Craig Lapin,

Marianne S. Muhlebach,

Kimberly J. Novak,

Sean Nguyen,

Lisa Saiman,

David P. Nicolau,

Joseph L. Kuti

Publication year - 2015

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkv289

Subject(s) - meropenem , cystic fibrosis , pharmacokinetics , medicine , tolerability , population pharmacokinetics , population , pharmacology , antibiotics , anesthesia , adverse effect , microbiology and biotechnology , biology , antibiotic resistance , environmental health

Meropenem is frequently used to treat pulmonary exacerbations in children with cystic fibrosis (CF) in the USA. Prolonged-infusion meropenem improves the time that free drug concentrations remain above the MIC (fT> MIC) in adults, but data in CF children are sparse. We describe the population pharmacokinetics, tolerability and treatment burden of prolonged-infusion meropenem in CF children.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research